Across organizations, RWE is increasingly used to describe patient journeys, support exploratory analyses, or generate publications but its real influence on clinical decision‑making remains inconsistent. This roundtable focuses on the non‑technical barriers that prevent RWE from shaping trial design, safety strategy, and development priorities – including timing, study framing, internal trust, and cross‑functional alignment.

Networking Discussion Questions:

• At what point in the clinical development lifecycle does RWE currently have the greatest potential to influence decisions – and where is that opportunity most often missed?
• What distinguishes RWE that genuinely informs clinical decisions from RWE that remains descriptive or retrospective?
• How do timing and sequencing affect whether RWE is acted upon or sidelined by clinical teams?
• Where do breakdowns in trust or communication most often occur between clinical development, epidemiology, and RWE teams – and how are organizations overcoming them?